NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.
Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.
Also In This 12-page Issue: NCI To Cut Budgets For New Grants By 29 Percent. R01s To Be Funded At 11th Percentile.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help